Faisal Khurshid

Stock Analyst at Leerink Partners

(4.27)
# 444
Out of 5,043 analysts
26
Total ratings
61.9%
Success rate
16.21%
Average return

Stocks Rated by Faisal Khurshid

Galapagos NV
Oct 21, 2025
Upgrades: Outperform
Price Target: $29$40
Current: $31.25
Upside: +28.00%
Contineum Therapeutics
Sep 25, 2025
Initiates: Outperform
Price Target: $20
Current: $11.09
Upside: +80.42%
Protagonist Therapeutics
Sep 12, 2025
Initiates: Outperform
Price Target: $73
Current: $75.28
Upside: -3.03%
Shattuck Labs
Aug 14, 2025
Maintains: Outperform
Price Target: $4$2
Current: $2.03
Upside: -1.66%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Outperform
Price Target: $88$102
Current: $110.17
Upside: -7.42%
AbCellera Biologics
Jul 7, 2025
Assumes: Outperform
Price Target: $5
Current: $5.80
Upside: -13.72%
Ironwood Pharmaceuticals
Apr 14, 2025
Maintains: Market Perform
Price Target: $3$1
Current: $1.65
Upside: -39.39%
Spyre Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $24.38
Upside: +84.58%
Nurix Therapeutics
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $11.88
Upside: +34.68%
Pliant Therapeutics
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33$2
Current: $1.78
Upside: +12.68%
Initiates: Outperform
Price Target: $16
Current: $0.98
Upside: +1,526.02%
Maintains: Outperform
Price Target: $60
Current: $61.14
Upside: -1.86%
Initiates: Outperform
Price Target: $80
Current: $93.21
Upside: -14.17%
Initiates: Outperform
Price Target: $15
Current: $3.98
Upside: +276.88%
Assumes: Outperform
Price Target: $7
Current: $10.51
Upside: -33.40%
Assumes: Outperform
Price Target: $45
Current: $17.47
Upside: +157.66%
Initiates: Outperform
Price Target: $7
Current: $1.27
Upside: +451.18%
Assumes: Outperform
Price Target: $8
Current: $5.41
Upside: +48.01%
Assumes: Outperform
Price Target: $5
Current: $0.83
Upside: +502.85%
Initiates: Outperform
Price Target: $11
Current: $5.93
Upside: +85.50%